Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Oct;30(5):2015-25.
doi: 10.1007/s10637-011-9776-4. Epub 2011 Dec 21.

A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma

Affiliations
Clinical Trial

A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma

Takuji Okusaka et al. Invest New Drugs. 2012 Oct.

Abstract

Background: SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We conducted a multicenter phase II trial in patients with HCC to evaluate the efficacy and safety of SM-11355, using a Zinostatin stimalamer suspension in iodized oil as a reference.

Methods: Patients with unresectable HCC were randomized 2:1 to receive administration of the SM-11355 or Zinostatin stimalamer suspension into the hepatic artery. A second injection was given 4-12 weeks later. Efficacy was evaluated by CT 3 months after treatment and categorized as therapeutic effect (TE) V to I, where TE V was defined as disappearance or 100% necrosis of all treated tumors.

Results: A total of 122 patients were evaluated for efficacy and toxicity (SM-11355, n = 83; Zinostatin stimalamer, n = 39). Baseline characteristics were similar in the two groups. The TE V rates were 26.5% (22/83) and 17.9% (7/39) in the SM-11355 and Zinostatin stimalamer groups, respectively. In the SM-11355 group,the most frequent drug-related adverse events (AEs) of ≥ grade 3 were elevated AST, elevated ALT, thrombocytopenia, and hyperbilirubinemia. The AEs with the largest difference between the two groups (SM-11355 vs. Zinostatin stimalamer) were hepatic vascular injury (0 vs. 48.4%) and eosinophilia (84.3 vs. 41.0%). The 2-year and 3-year survival rates were 75.9% vs. 70.3% and 58.4% vs. 48.7%, respectively.

Conclusions: The results suggest that SM-11355 in iodized oil has similar efficacy to Zinostatin stimalamer and that repeated dosing of SM-11355 is possible without hepatic vascular injury in cases of relapse.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structural formula of SM-11355
Fig. 2
Fig. 2
Study flow diagram
Fig. 3
Fig. 3
Cumulative survival rate
Fig. 4
Fig. 4
Changes in Child-Pugh Classification

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma: an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23(11):1535–1547. doi: 10.1111/j.1365-2036.2006.02932.x. - DOI - PubMed
    1. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumore activity. Jpn J Cancer Res. 1986;77(6):523–525. - PubMed
    1. Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin / lipiodol. Br J Cancer. 2003;89(9):1614–1619. doi: 10.1038/sj.bjc.6601318. - DOI - PMC - PubMed
    1. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004;22(2):169–176. doi: 10.1023/B:DRUG.0000011793.72775.d1. - DOI - PubMed

Publication types